Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jazz Pharmaceuticals has the GF Score of 72, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Jazz Pharmaceuticals
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Jazz Pharmaceuticals (FRA:J7Z) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Jazz Pharmaceuticals GF Score Related Terms
FRA:J7Z vs BBIO, EXEL, IONS: GF Score Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's GF Score distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's GF Score falls into.
Jazz Pharmaceuticals (FRA:J7Z) has a GF Score of 72 as of Jul. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Jazz Pharmaceuticals and its competitors. This is 19% below median its historical median of 89.00. Over the past decade, Jazz Pharmaceuticals' GF Score has ranged from 27.00 to 100.00.
Is Jazz Pharmaceuticals' GF Score too high?
Jazz Pharmaceuticals' current GF Score of 72 is 19% below median its 10-year median of 89.00. Over the past 10 years, this metric has ranged from a low of 27.00 to a high of 100.00. Overall, Jazz Pharmaceuticals has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' GF Score compare to BBIO and EXEL?
Jazz Pharmaceuticals' GF Score of 72 can be compared against companies in the Biotechnology industry. Historically, Jazz Pharmaceuticals' own GF Score has ranged from 27.00 to 100.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current GF Score is 72, which is 19% below median its own 10-year median of 89.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €130.60, compared to a current price of €207.40 — trading 58.8% above its estimated fair value. The current GF Score is 72, which is 19% below median its 10-year median of 89.00. Jazz Pharmaceuticals' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current GF Score is 72 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €207.40 is trading 58.8% above its estimated GF Value™ of €130.60.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:J7Z:
GF Score: 72 (19% below median its 10-year median of 89.00)
GF Value™: €130.60 vs. price of €207.40 (58.8% above fair value)
No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
72GF Score
Get the complete analysis for FRA:J7Z
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J7Z has been successfully added to your 
